Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
February 2016
-
Story From Our Labs
5 tips for making smart decisions on research projects
Make smart decisions about your research projects.
-
Press release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as… -
In The News
Novartis Access perspectives: Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world -
Press release
Novartis shareholders approve all resolutions proposed by Board of Directors
Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as… -
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions… -
Press release
Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des… -
Story From Our Labs
CRISPR genome editing fuels cancer drug discovery
Genome editing advances drug discovery in biomedical research.
-
Press release
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult… -
Press release
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or… -
Story Access to Healthcare
Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.
-
In The News
Joe Jimenez on how to improve healthcare
In an op ed with Foreign Affairs, Joe Jimenez explains why outcomes, innovation and collaboration are the keys to improving healthcare worldwide. -
Story From Our Labs
Rediscovering the power of nature’s exquisite complexity
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research